• Je něco špatně v tomto záznamu ?

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

J. Han van Krieken, G. Kafatos, J. Bennett, L. Mineur, J. Tomášek, E. Rouleau, P. Fabian, G. De Maglio, P. García-Alfonso, G. Aprile, P. Parkar, G. Downey, G. Demonty, J. Trojan,

. 2017 ; 17 (1) : 798. [pub] 20171128

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033513

BACKGROUND: In Europe, treatment of metastatic colorectal cancer (mCRC) with panitumumab requires prior confirmation of RAS wild-type mutation status. Two studies - a physician survey and a medical records review (MRR) - were conducted to evaluate the use of panitumumab and awareness among prescribing oncologists of the associated RAS testing requirements in clinical practice. METHODS: Both studies enrolled participants from nine European countries and were carried out in three consecutive rounds. Rounds 1 and 2 (2012-2013) examined KRAS (exon 2) testing only; the results have been published in full previously. Round 3 (2014-2015) examined full RAS testing (exons 2, 3, 4 of KRAS and NRAS) and was initiated following a change in prescribing guidelines, from requiring KRAS alone to requiring full RAS testing. For the physician survey, telephone interviews were conducted with oncologists who had prescribed panitumumab to patients with mCRC in the previous 6 months. For the MRR, oncologists were asked to provide anonymised clinical information, extracted from their patients' records. RESULTS: In Round 3, 152 oncologists and 131 patients' records were included in the physician survey and MRR, respectively. In Round 3 of the physician survey, 95.4% (n = 145) of participants correctly identified that panitumumab should only be prescribed in RAS wild-type mCRC compared with 99.0% (n = 298) of 301 participants in Rounds 1 and 2, responding to the same question about KRAS testing. In Round 3 of the MRR, 100% (n = 131) of patients included in the study had confirmed KRAS or RAS wild-type status prior to initiation of panitumumab compared with 97.7% (n = 299) of 306 patients in Rounds 1 and 2 (KRAS only). Of those patients in Round 3, 83.2% (n = 109) had been tested for RAS status and 16.8% (n = 22) had been tested for KRAS status only. CONCLUSIONS: Physicians' adherence to prescribing guidelines has remained high over time in Europe, despite the change in indication for panitumumab treatment, from KRAS to RAS wild-type mCRC. Additionally, this study demonstrates the uptake of full RAS testing among the majority of oncologists and pathologists.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033513
003      
CZ-PrNML
005      
20181022130427.0
007      
ta
008      
181008s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-017-3740-4 $2 doi
035    __
$a (PubMed)29183279
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Han van Krieken, J $u Radboud University Medical Center, Nijmegen, Netherlands. Han.vanKrieken@radboudumc.nl.
245    10
$a Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review / $c J. Han van Krieken, G. Kafatos, J. Bennett, L. Mineur, J. Tomášek, E. Rouleau, P. Fabian, G. De Maglio, P. García-Alfonso, G. Aprile, P. Parkar, G. Downey, G. Demonty, J. Trojan,
520    9_
$a BACKGROUND: In Europe, treatment of metastatic colorectal cancer (mCRC) with panitumumab requires prior confirmation of RAS wild-type mutation status. Two studies - a physician survey and a medical records review (MRR) - were conducted to evaluate the use of panitumumab and awareness among prescribing oncologists of the associated RAS testing requirements in clinical practice. METHODS: Both studies enrolled participants from nine European countries and were carried out in three consecutive rounds. Rounds 1 and 2 (2012-2013) examined KRAS (exon 2) testing only; the results have been published in full previously. Round 3 (2014-2015) examined full RAS testing (exons 2, 3, 4 of KRAS and NRAS) and was initiated following a change in prescribing guidelines, from requiring KRAS alone to requiring full RAS testing. For the physician survey, telephone interviews were conducted with oncologists who had prescribed panitumumab to patients with mCRC in the previous 6 months. For the MRR, oncologists were asked to provide anonymised clinical information, extracted from their patients' records. RESULTS: In Round 3, 152 oncologists and 131 patients' records were included in the physician survey and MRR, respectively. In Round 3 of the physician survey, 95.4% (n = 145) of participants correctly identified that panitumumab should only be prescribed in RAS wild-type mCRC compared with 99.0% (n = 298) of 301 participants in Rounds 1 and 2, responding to the same question about KRAS testing. In Round 3 of the MRR, 100% (n = 131) of patients included in the study had confirmed KRAS or RAS wild-type status prior to initiation of panitumumab compared with 97.7% (n = 299) of 306 patients in Rounds 1 and 2 (KRAS only). Of those patients in Round 3, 83.2% (n = 109) had been tested for RAS status and 16.8% (n = 22) had been tested for KRAS status only. CONCLUSIONS: Physicians' adherence to prescribing guidelines has remained high over time in Europe, despite the change in indication for panitumumab treatment, from KRAS to RAS wild-type mCRC. Additionally, this study demonstrates the uptake of full RAS testing among the majority of oncologists and pathologists.
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a antitumorózní látky $x terapeutické užití $7 D000970
650    _2
$a kolorektální nádory $x farmakoterapie $x genetika $7 D015179
650    _2
$a Evropa $7 D005060
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a GTP-fosfohydrolasy $x genetika $7 D020558
650    _2
$a genetické testování $7 D005820
650    _2
$a dodržování směrnic $7 D019983
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a chorobopisy $7 D008499
650    _2
$a membránové proteiny $x genetika $7 D008565
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a lékaři $7 D010820
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a lékařská praxe - způsoby provádění $7 D010818
650    _2
$a protoonkogenní proteiny p21(ras) $x genetika $7 D016283
650    _2
$a průzkumy a dotazníky $7 D011795
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a přehledy $7 D016454
700    1_
$a Kafatos, George $u Amgen Ltd, Uxbridge, UK.
700    1_
$a Bennett, James $u Amgen Ltd, Uxbridge, UK.
700    1_
$a Mineur, Laurent $u Institute Sainte Catherine, Avignon, France.
700    1_
$a Tomášek, Jiří $u Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Rouleau, Etienne $u Curie Institute, Paris, France.
700    1_
$a Fabian, Pavel $u Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a De Maglio, Giovanna $u University and General Hospital, Udine, Italy.
700    1_
$a García-Alfonso, Pilar $u Gregorio Marañón Hospital, Madrid, Spain.
700    1_
$a Aprile, Giuseppe $u University and General Hospital, Udine, Italy.
700    1_
$a Parkar, Parijan $u Amgen Ltd, Uxbridge, UK.
700    1_
$a Downey, Gerald $u Amgen Ltd, Cambridge, UK.
700    1_
$a Demonty, Gaston $u Amgen GmbH, Zug, Switzerland.
700    1_
$a Trojan, Jörg $u University Hospital, Frankfurt, Germany.
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 17, č. 1 (2017), s. 798
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29183279 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181022130933 $b ABA008
999    __
$a ok $b bmc $g 1340185 $s 1030507
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 17 $c 1 $d 798 $e 20171128 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Možnosti archivace